1,288 patients for whom data were collected between August 2005 and March 2008. Among these, the investigation was limited to 1,254 patients who were administered monteplase for the first time. Acute PE severity was categorized as (1) cardiopulmonary arrest (CPA)/collapse group, (2) massive (unstable hemodynamics without CPA/collapse), (3) submassive (stable hemodynamics with right ventricular dysfunction: RVD) and (4) non-massive (stable hemodynamics without RVD) in accordance with the classification system of the Japanese Circulation Society (JCS), rated through assessment of hemodynamics and RVD on echocardiography. 2 Efficacy analysis was performed in the CPA/collapse, massive and submassive patient groups. The non-massive and unknown severity patients were included only in the safety analysis.
Study Population
Data were collected for a total of 1,254 patients, 13 of whom were excluded from the safety analysis because they were duplicate cases or had deficiencies in the safety information. The remaining 1,241 patients were included in the safety analysis. In the efficacy analysis, 767 patients fulfilling the following 2 criteria were included: (1) acute PE confirmed by enhanced computed tomography (CT), pulmonary angiography (PAG) or perfusion scan, or right heart thrombus on echocardiography; and (2) monteplase administered intravenously by single bolus injection. The remaining 474 cases that did not correspond to these criteria were excluded from the efficacy analysis. Among the 767 patients, acute PE was categorized as CPA/ collapse in 85 cases, massive in 217 cases and submassive in 465 cases (Figure 1 ).
Pulmonary Circulation and Clinical Efficacy
Pulmonary circulation was evaluated on the basis of enhanced CT, PAG or perfusion scan. Clinical efficacy was evaluated by the physician, based on acute PE-derived clinical symptoms, signs and RVD, in addition to pulmonary circulation evaluation. In each evaluation, the response rate (based on a comparison of pre-and post-treatment conditions) was analyzed in relation to factors such as monteplase dose, patient age, and acute PE severity.
Changes in the incidence of clinical symptoms and RVD were compared among the CPA/collapse, massive and submassive groups.
Prognosis
The 30-day overall mortality rate after monteplase administration was calculated for the 767 patients. Survival rate was analyzed in relation to acute PE severity and implantation of inferior vena cava (IVC) filters.
Bleeding Complications and ICH
A total of 1,241 patients were included in the safety analysis to investigate the occurrence of adverse effects within 30 days after monteplase administration. The definition of adverse effects was medically undesired or unexpected disorders for which a causal relationship to monteplase could not be ruled out by a physician and/or the drug safety evaluation committee. Among the potential adverse effects, particular focus was placed on hemorrhagic events. Severe bleeding was judged by a physician and the committee. Among bleeding events, brain parenchymal bleeding, subarachnoid hemorrhage and subdural hematoma were considered to represent ICH.
Statistical Analysis
Chi-square tests were performed for the efficacy and safety analysis cases to compare patient characteristics between the 3 acute PE severity groups. Changes in symptoms and RVD index (absence/presence) were compared among the 3 groups using a generalized estimating equations approach.
Multivariate logistic regression analysis was carried out using a full model to identify the background characteristics of patients associated with the onset of severe bleeding complications and ICH. The survival rate was estimated using the Kaplan-Meier method, and log-rank testing was used to analyze relationships for each group. In all analyses, the significance level was set at 5% (2-tailed). 
Results
Characteristics of the 3 Acute PE Severity Groups (Table 1) Of the 767 patients evaluated, 60.5% were female, and 24.6% were elderly (≥75 years old). However, no significant differences in the male-to-female ratio, percentage of elderly patients and doses of monteplase were seen among the 3 groups. Incidences of syncope (100.0%) and cyanosis (47.1%) at acute PE onset, surgery (21.2%) and fracture (12.9%), right bundle branch block (43.6%) and RV dilatation and/or hypokinesis (93.2%) were significantly higher in the CPA/collapse group than in the others. Incidences of dyspnea (86.2%), T-wave inversion in leads V1-3 (52.5%) and abnormal tricuspid regurgitation pressure gradient (TRPG) (62.8%) were highest in the submassive group. In terms of combined therapies other than thrombolytic therapy, frequencies of catheter intervention (30.6%), surgical embolectomy (3.5%) and percutaneous cardiopulmonary support (PCPS) (42.4%) were highest in the CPA/ collapse group, and IVC filter implantation was more frequent in the submassive group (48.8%). Warfarin was more frequent- 
Pulmonary Circulation and Clinical Efficacy (Table 2)
The response rate to monteplase was 94.6% in terms of the pulmonary circulation evaluation and 93.3% in terms of the clinical efficacy evaluation. No significant differences in response rate within both indicators were seen depending on monteplase dose or patient age. On the other hand, a significant difference was seen depending on severity, and efficacy rates were lower in the CPA/collapse group (pulmonary circulation evaluation, 85.3%; clinical efficacy evaluation, 76.7%) than in the massive or submassive group.
Changes in Symptoms, Signs and Echocardiographic Findings
The most frequent symptom and sign before monteplase administration was dyspnea (80.6%) and shock (33.9%), respectively, both of which disappeared rapidly after monteplase administration, remaining in 38.6% and 11.6% at 1 h after, in 12.3% and 4.8% at 24-48 h after, and in 3.2% and 2.2% at the time of final evaluation (median, 168 h after monteplase administra- at the time of final evaluation, respectively. Time courses for symptoms and RVD findings were compared among the 3 groups. No significant differences were seen among the 3 groups in the time course of the incidences of dyspnea (Figure 2A) and RV dilatation and/or hypokinesis ( Figure 2B ).
Heart rate and respiratory rate reduced from pretreatment levels by 24.0 beats/min and 7.5 breaths/min, respectively, at the time of last evaluation. Moreover, systolic blood pressure increased by 8.7 mmHg from the pretreatment level (unpublished data).
Prognosis
Of the 767 patients in the efficacy analysis, 82 (10.7%) died within 30 days. The main cause of death was the first episode of PE in 41 patients, recurrent PE in 9 patients, and hemorrhagic events in 11 patients. The survival rate for all 767 patients was 89.2% ( Figure 3A ). Significant differences in sur- Univariate and multivariate logistic regression analyses of onset of severe bleeding complications in the safety analysis. 1 Among the safety analysis population (n=1,241), 138 patients with missing values were excluded and the remaining 1,103 patients were used for multivariate logistic regression analysis. 2 Age of 1 patient was unknown. 3 Comparison of each dose level with <13,750 IU/kg as reference. 4 Comparison between patients with and without CPA/collapse. 5 Comparison between patients with and without shock. OR, odds ratio; CI, confidence interval. Other abbreviations as in Table 1 . NIWA A et al.
vival rate were seen among the 3 severity groups. The survival rate at 30 days was 96.3% in the submassive group, 93.0% in the massive group and 41.2% in the CPA/collapse group ( Figure 3B) . Moreover, survival rate was significantly lower in the absence of IVC filter implantation (84.0%) than in filterimplanted patients (95.2%) ( Figure 3C ). Univariate and multivariate logistic regression analyses of onset of ICH in the safety analysis. 1 Among the safety analysis population (n=1,241), 137 patients with missing values were excluded and the remaining 1,104 patients were used for multivariate logistic regression analysis. 2 Age of 1 patient was unknown. 3 Comparison of each dose level with <13,750 IU/kg as reference. 4 Comparison between patients with and without CPA/collapse. 5 Comparison between the patients with and without shock. ICH, intracranial hemorrhage. Other abbreviations as in Tables 1,4 . Thrombolysis With t-PA in Acute PE 14 cases, hemorrhagic cerebral infarction and subdural hematoma in 2 cases each, and brainstem hemorrhage, cerebellar hemorrhage and subarachnoid hemorrhage in 1 case each. A total of 6 patients had a fatal outcome, including 2 patients with cerebral hemorrhage and 1 patient each with subarachnoid hemorrhage, hemorrhagic cerebral infarction, cerebellar hemorrhage and subdural hematoma. In the comparisons by the severity, ICH occurred in 4 patients (2.6%) in the CPA/collapse group, in 8 patients (2.8%) in the massive group, in 5 patients (0.8%) in the submassive group and in 4 patients in the other groups. Multivariate analysis revealed no significant factors associated with the onset of ICH ( Table 5) .
Bleeding Complications and ICH

Discussion
The present study provides data from the first large-scale postmarketing surveillance in Japan on thrombolysis for acute PE. Acute PE patients diagnosed by enhanced CT, PAG and perfusion scan were included in this study population. According to the committee of the Japan Radiological Society and Japanese Collage of Radiology, perfusion scan combined with chest Xray other than ventilation scan has been reported to offer sufficient diagnostic power on its own. 3 In terms of efficacy, the response rate was 93-94% for both the pulmonary circulation and clinical efficacy evaluations, supporting the results of pre-marketing clinical trials for monteplase. 4 These results were unaffected by factors such as monteplase dose, patient age, or acute PE severity. As for the thrombolytic effects on acute PE patients with shock, JerjesSanchez et al reported their randomized investigation of 8 cases in which they compared thrombolytic-treated massive cases (0% mortality) with untreated massive cases (100% mortality), 5 but this type of comparison is currently impossible for ethical reasons. In Japan, in-hospital mortality rates with and without thrombolytic therapy in massive cases are 20% and 50%, respectively (P<0.005). 6 This mortality rate with thrombolysis is consistent with the findings of the present study, in which the mortality rate at 30 days was 21.6% in both the massive and CPA/collapse groups. When analysis was confined to patients developing CPA/collapse, the mortality rate was 58.8% in the present study, comparable to a previously reported 30-day mortality rate with cardiac arrest of 52.4% 7 and an in-hospital death rate with cardiac arrest of 70%. 8 The mortality rate of the submassive group (3.7%) in the present study was also similar to those previously reported (2.7% 7 and 3.4% 9 ).
Regarding placement of IVC filters, mortality rates by 30 days were significantly lower for patients with implanted filters (4.7%) than for patients without (16.0%). This supports previous findings that IVC filters significantly lowered the 30-day mortality rate (OR, 0.16), 7 and reduced mortality rates by 90 days (hazard ratio, 0.12). 10 All these results show that this device might be useful for massive and submassive cases.
The clinical symptoms improved rapidly after monteplase administration because monteplase has a relatively long halflife, enabling maintenance of a high effective plasma concentration for potent fibrinolytic activity, 11 and all medicines administrated intravenously reach the pulmonary arterial thrombus and demonstrate activity. On the other hand, improvement of RVD after treatment was relatively moderate. RV dilatation and/or hypokinesis, as well as abnormal TRPG, remained in more than 20% of cases at the time of last evaluation. This indicates that some patients may experience acute episodes overlaying the chronic PE.
According to the ESC guidelines, routine administration of thrombolytics is not recommended for normotensive patients with RVD. 12 Likewise, under the current Japanese guidelines, the recommendation level is Class IIa, and no efficacy of thrombolytic therapy in submassive cases has yet been confirmed. 2 Among submassive cases in Nakamura et al's study, no significant difference in in-hospital mortality rate was evident between patients with (8%) and without (4%) thrombolysis. 6 A current meta-analysis also reported no significant benefits in mortality rate when thrombolysis was compared with anticoagulation among submassive cases. 13 In the present study, the improvement rate for clinical symptoms (dyspnea) or RVD (RV dilatation and/or hypokinesis) after monteplase therapy did not differ significantly among the CPA/collapse, massive and submassive groups. The rapid clinical improvement with monteplase in the submassive group may suggest its use in preventing escalation of treatment and deterioration of systemic conditions.
In the safety analysis, severe bleeding complications developed in 8.1% of patients in the present study. In the literature, the incidence of severe bleeding after thrombolytic therapy using urokinase and t-PA has been reported as 13%, 14 and frequencies of bleeding complications requiring blood transfusion have been reported as 7.1% 7 in Japan and approximately 20% in Western countries. 15 The 23.4% frequency of severe hemorrhage for the CPA/collapse group was almost the same level as in a previous report (18%). 16 In the present study, CPA/collapse and shock were identified as independent predictors of severe hemorrhage. Fiumara et al highlighted hemodynamic instability as an important factor contributing to severe hemorrhage. 17 Moreover, in CPA/collapse cases, there is a high rate of performing PAG and PCPS. It is considered that the vascular puncture associated with these procedures might be related to the high incidence of severe bleeding complications in severe acute PE patients. In the present study, the time from acute PE onset to monteplase administration and prolonged immobilization was found to be an independent predictor of severe bleeding complications. However, the clinical significance of this factor was unclear (OR=0.995), and critically ill patients may be experiencing some changes in coagulation-hemostasis and have a heightened sensitivity to thrombolytic agents.
In this study, ICH developed in 1.7% of patients, which is comparable to that reported by Nakamura et al (1.65%). 14 In Western countries, the range of reported incidence of ICH is similar, ranging from 0.5% 18 to 3.0% 19 to 5.0%. 17 In the present study, the incidence of ICH was not dependent on monteplase dose or acute PE severity.
Kanter et al identified age, weight, history of cerebrovascular disorders and diastolic blood pressure as risk factors for ICH after acute PE thrombolysis. 20 In univariate analyses of ICH, the frequency of ICH was high in female patients, elderly patients and patients with a history of cerebrovascular disorders and shorter delay to the start of monteplase administration, but these factors were not significant in multivariate regression analyses.
In general, bleeding complications occur more frequently with thrombolytic therapy than with anticoagulation alone. When limited to submassive cases, severe bleeding occurs with a significantly high incidence in the thrombolytic group compared with the heparin group (9.4% vs. 0% 21 ; 21.9% vs. 7.8% 22 ). Regarding ICH, no significant differences were observed between these 2 strategies in the above 2 studies (4.7% vs. 0% 21 ; 1.2% vs. 0.4% 22 ). In the present study, severe hemorrhagic events and ICH in the submassive group occurred in 4.2% and 0.8%, respectively. Although these incidences with monteplase treatment were almost comparable to the previously reported ranges with anticoagulation therapy, thrombolytic therapy NIWA A et al.
should be instituted carefully after detailed risk-benefit assessment in submassive cases.
Regarding the optimum dose of monteplase for Japanese acute PE patients, no clear correlations were seen between the dose of monteplase and efficacy indices or the incidence of severe hemorrhage or ICH. This suggests that sufficient efficacy and safety can be achieved with a dose of approximately 13,750 IU/kg (ie, the lower limit of the current approved dose for acute PE).
Study Limitations
As this study was designed as an observational study of clinical cases, the investigation was based on clinical efficacy and the safety judgment by the physicians. For example, no criteria for a judgment of abnormality were incorporated for echocardiographic RVD or clinical symptoms and signs. No specific uniform criteria, such as blood transfusion or changes in laboratory test values, have been set to judge the severity of hemorrhagic events for safety reasons. Needless to say, monteplase-treated cases could not be compared with untreated cases in the present study.
Conclusions
Our survey of thrombolytic therapy for acute PE in Japan revealed response rates as high as 93% in both pulmonary circulation resumption and clinical efficacy, regardless of basic patient characteristics or acute PE severity. Survival rate by 30 days was 89.2% overall, as high as 96.3% in the submassive group, 93.0% in the massive group and 41.2% in the CPA/collapse group. Safety analysis showed that incidences of severe bleeding complications (8.1%) and ICH (1.7%) were within the previously reported ranges. The present results demonstrate that thrombolytic therapy is highly effective in Japanese acute PE patients, offering acceptable safety. However, careful attention should be paid to bleeding complications.
